Integrating inflammatory biomarkers with PSA or mpMRI may enhance diagnostic accuracy and guide personalized immunotherapeutic strategies, such as targeting NF-κB or tumor-associated macrophages via CDK12/13 inhibition or CD47 blockade. The gene discussed is NFKB1; the disease is neoplasm.